Correction: Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway

Joshua E Allen^{1

2}, Gabriel Krigsfeld¹, Luv Patel¹, Patrick A Mayes¹, David T Dicker^{1

3}, Gen Sheng Wu⁴, Wafik S El-Deiry^{5

6}

Affiliations

¹ Departments of Medicine, Genetics, and Pharmacology, Laboratory of Molecular Oncology and Cell Cycle Regulation, University of Pennsylvania School of Medicine, Philadelphia, 19104, PA, USA.
² Current affiliation: Oncoceutics, Inc., Hummelstown, PA, USA.
³ Department of Medical Oncology and Molecular Therapeutics Program, Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Fox Chase Cancer Center, Philadelphia, 19111, PA, USA.
⁴ Department of Pathology, Program in Molecular Biology and Genetics, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, 48201, USA.
⁵ Departments of Medicine, Genetics, and Pharmacology, Laboratory of Molecular Oncology and Cell Cycle Regulation, University of Pennsylvania School of Medicine, Philadelphia, 19104, PA, USA. wafik.eldeiry@fccc.edu.
⁶ Department of Medical Oncology and Molecular Therapeutics Program, Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Fox Chase Cancer Center, Philadelphia, 19111, PA, USA. wafik.eldeiry@fccc.edu.

Published Erratum

Joshua E Allen et al. Mol Cancer. 2024.

. 2024 Oct 18;23(1):233.

doi: 10.1186/s12943-024-02158-w.

Joshua E Allen^{1

2}, Gabriel Krigsfeld¹, Luv Patel¹, Patrick A Mayes¹, David T Dicker^{1

3}, Gen Sheng Wu⁴, Wafik S El-Deiry^{5

6}

¹ Departments of Medicine, Genetics, and Pharmacology, Laboratory of Molecular Oncology and Cell Cycle Regulation, University of Pennsylvania School of Medicine, Philadelphia, 19104, PA, USA.
² Current affiliation: Oncoceutics, Inc., Hummelstown, PA, USA.
³ Department of Medical Oncology and Molecular Therapeutics Program, Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Fox Chase Cancer Center, Philadelphia, 19111, PA, USA.
⁴ Department of Pathology, Program in Molecular Biology and Genetics, Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, 48201, USA.
⁵ Departments of Medicine, Genetics, and Pharmacology, Laboratory of Molecular Oncology and Cell Cycle Regulation, University of Pennsylvania School of Medicine, Philadelphia, 19104, PA, USA. wafik.eldeiry@fccc.edu.
⁶ Department of Medical Oncology and Molecular Therapeutics Program, Laboratory of Translational Oncology and Experimental Cancer Therapeutics, Fox Chase Cancer Center, Philadelphia, 19111, PA, USA. wafik.eldeiry@fccc.edu.

No abstract available

Erratum for

Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway.
Allen JE, Krigsfeld G, Patel L, Mayes PA, Dicker DT, Wu GS, El-Deiry WS. Allen JE, et al. Mol Cancer. 2015 May 1;14:99. doi: 10.1186/s12943-015-0346-9. Mol Cancer. 2015. PMID: 25927855 Free PMC article.

1. Allen JE, Krigsfeld G, Patel L, et al. Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway. Mol Cancer. 2015;14:99. 10.1186/s12943-015-0346-9. - PMC - PubMed